Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma
Retrieved on:
Tuesday, April 5, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, Esophageal cancer, Adenocarcinoma, LinkedIn, Diagnosis, Agilent Technologies, CE, Death, ESCC, Mortality, NYSE, IHC, Survival, Neoplasm, Incidence, Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, Marie Cassidy, Histology, Quality of life, Lead, Software, Twitter, Hope, Matthew 28:8, Squamous cell carcinoma, Union, Solution, Nivolumab, Fluoropyrimidine, News, Bristol Myers Squibb, PD-L1, Patient, Ipilimumab, Pharmaceutical industry, Facebook
The two most common types of esophageal cancer are squamous cell carcinoma and adenocarcinoma, which account for approximately 85% and 15% of all esophageal cancers, respectively, though esophageal tumor histology can vary by region and country.
Key Points:
- The two most common types of esophageal cancer are squamous cell carcinoma and adenocarcinoma, which account for approximately 85% and 15% of all esophageal cancers, respectively, though esophageal tumor histology can vary by region and country.
- PD-L1 is a critical biomarker for response to anti-PD-1 therapies, including the immunotherapeutic agent OPDIVO based on the Phase 3 CheckMate-648 trial results.
- We greatly value our relationship with Bristol Myers Squibb, and are committed to continuing developing and commercializing market-leading companion diagnostic products.
- Agilent is the worldwide leader in partnering with pharmaceutical companies to develop IHC-based diagnostics for targeted cancer therapy.